Home › Head and Neck Squamous Cell Carcinoma › Kentucky › Louisville
Head and Neck Squamous Cell Carcinoma clinical trials in Louisville, KY
11 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Louisville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
- Site#0111, Louisville
- Site#0115, Louisville
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Norton Cancer Institute, Louisville
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Norton Cancer Institute, Louisville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Baptist Health Floyd, New Albany · 4 mi away
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RecruitingPhase 3
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- Norton Cancer Institute, Louisville
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
RecruitingPhase 1/2
- Norton Cancer Institue Downtown, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- Norton Cancer Institute /ID# 248903, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 115, Louisville
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- New York City, NY39 studies
- Nashville, TN39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Philadelphia, PA26 studies
- Chicago, IL26 studies
- Atlanta, GA24 studies
- San Antonio, TX22 studies
- Pittsburgh, PA22 studies
Other studies in Louisville
- Non-Small Cell Lung Cancer22 studies
- Obesity17 studies
- Overweight15 studies
- Cancer (all types)14 studies
- Heart Failure13 studies
- Acute Myeloid Leukemia12 studies
- Multiple Myeloma12 studies
- Ovarian Cancer12 studies
- Breast Cancer11 studies
- Lung Cancer11 studies
- Melanoma10 studies
- Prostate Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.